Quantum Genesis AI Corp. (QGAI) stock: key figures, P/E, revenue and dividend
Materials · United States
Quantum Genesis AI Corp. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -180,537.00 USD |
| EBIT | -178,037.00 USD |
| Net income | -199,269.00 USD |
| Diluted EPS – continuing operations | -0.01 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Quantum Genesis AI Corp.
Quantum Genesis AI Corp., a biotransformation company, focuses on advancing enzyme-based solutions for pharmaceutical manufacturing. It utilizes customer centric research to enhance enzyme activity, by applying quantum mechanics, molecular modelling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support production. The company was formerly known as Quantumzyme Corp. and changed its name to Quantum Genesis AI Corp. in February 2026. Quantum Genesis AI Corp. was incorporated in 2015 and is based in San Diego, California.
More stocks
- Power REIT (PW)
- SenesTech, Inc. (SNES)
- HealthLynked Corp (HLYK)
- VivoSim Labs, INC. (VIVS)
- OFA Group (OFAL)
- KALA BIO, Inc. (KALA)
- My City Builders, Inc. (MYCB)
- Dror Ortho-Design, Inc. (DROR)
- GBT Technologies Inc. (GTCH)
- Nuwellis, Inc. (NUWE)
- CV Sciences, Inc. (CVSI)
- PSQ Holdings, Inc. (PSQH)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.